Pharmacological management of behavioral symptoms associated with dementia

Table 1 Comparison of studies supporting or negating the mortality risk of antipsychotic medications[49]

Ref.	Type	Population	Comment
Schneider et al[50]	Meta-analysis; n = 5110	Mixed	Analyses of survival and causes of death needed; MR increased
Suh et al[51]	Prospective 1-yr study; n = 273	NH patients	MR not increased
Raivio et al[52]	Prospective 2-yr study; n = 254	NH patients	Very frail patients; restraints increased risk of mortality; MR not increased
Ballard et al[53]	Randomized, placebo-controlled, 1-yr study; n = 165	NH patients	MR increased
Gardette et al[47]	Prospective cohort 3.5-yr study; n = 534	Outpatients	Medications not independent predictor for mortality when adjusted for dementia severity; MR increased
Gisev et al[54]	Population-based cohort 9-yr study; n = 332	Outpatients	Highest risk in patients with baseline respiratory disease; MR increased
Huybrechts et al[55]	Population-based cohort 180-d study; n = 75445	NH patients	MR increased
Kales et al[46]	Retrospective cohort 180-d study; n = 33604	Outpatients	Highest risk with haloperidol; MR increased
Langballe et al[56]	Retrospective cohort 6-yr study; n = 26940	Outpatients	Limited adjustment in analysis; diagnosis based on prescription of antidementia drugs; MR increased
Lopez et al[26]	Prospective cohort 22-yr study with 4.3-yr follow-up; n = 957	Outpatients	Psychiatric symptoms increases risk of mortality; MR not increased
Arai et al[48]	Prospective cohort 10-wk study; n = 6000	Mixed	Preliminary finding; MR not increased

Reproduced with permission from Psychiatric Times ©2014. NH: Nursing home; MR: Mortality risk.